valproic acid has been researched along with Autosomal Dominant Myotubular Myopathy in 1 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Excerpt | Relevance | Reference |
---|---|---|
"X-linked myotubular myopathy (XLMTM) is a fatal neuromuscular disorder caused by loss of function mutations in MTM1." | 1.72 | X-linked myotubular myopathy is associated with epigenetic alterations and is ameliorated by HDAC inhibition. ( Alvi, SA; Beggs, AH; Bonnemann, CG; Celik, A; Chater-Diehl, E; Chicanne, G; Combes-Soia, L; Dowling, JJ; Froment, C; Genetti, CA; Ghahramani-Seno, MM; Goodman, SJ; Maani, N; Mansat, M; Monis, S; Muntoni, F; Pannia, E; Payrastre, B; Sabha, N; Sarikaya, E; Uusküla-Reimand, L; Viaud, J; Volpatti, JR; Weksberg, R; Wilson, MD; Yuki, KE, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Volpatti, JR | 1 |
Ghahramani-Seno, MM | 1 |
Mansat, M | 1 |
Sabha, N | 1 |
Sarikaya, E | 1 |
Goodman, SJ | 1 |
Chater-Diehl, E | 1 |
Celik, A | 1 |
Pannia, E | 1 |
Froment, C | 1 |
Combes-Soia, L | 1 |
Maani, N | 1 |
Yuki, KE | 1 |
Chicanne, G | 1 |
Uusküla-Reimand, L | 1 |
Monis, S | 1 |
Alvi, SA | 1 |
Genetti, CA | 1 |
Payrastre, B | 1 |
Beggs, AH | 1 |
Bonnemann, CG | 1 |
Muntoni, F | 1 |
Wilson, MD | 1 |
Weksberg, R | 1 |
Viaud, J | 1 |
Dowling, JJ | 1 |
1 other study available for valproic acid and Autosomal Dominant Myotubular Myopathy
Article | Year |
---|---|
X-linked myotubular myopathy is associated with epigenetic alterations and is ameliorated by HDAC inhibition.
Topics: Animals; Disease Models, Animal; Epigenesis, Genetic; Mice; Muscle, Skeletal; Myopathies, Structural | 2022 |